|
Gregory M. Zinkl, Ph.D. is a biotechnology patent attorney with Dykema's Pharmaceutical and Medical Device Team. Based in Dykema's Chicago Office, Dr. Zinkl's intellectual property practice has a global reach and includes drafting patent applications, prosecuting patent and trademark applications, and advising clients on complex scientific matters. He represents a variety of start-up biotech ventures and established pharmaceutical companies that require top-tier IP and patent prosecution counsel in both the United States and abroad.
Prior to becoming an attorney, Dr. Zinkl did post-doctoral research at the University of Chicago, concentrating in the areas of plant cell biology and genetics. This scientific foundation, coupled with his legal background, is particularly valuable to biotech clients around the world that seek IP counsel on highly technical, specialized aspects of biology, chemistry and other related fields. Dr. Zinkl's patent work encompasses technologies such as gene therapy; stem cell research; antibody-, gene- and cell-based diagnostic testing; recombinant antibodies and enzymes; polymerase chain reaction (PCR) technologies; and plant biology.
Dr. Zinkl provides legal support in due diligence, invalidity, inventorship and freedom-to-operate opinions. He also is called upon to provide IP litigation support on biotech and scientific aspects of inventorship and patent infringement. He is the author of numerous articles on plant and cell biology that have been published in scientific journals.
Experience
Preparing and procuring patents in a broad range of biotechnologies, including gene therapy, genomics, transgenic animals, diagnostics, virology, immunology, tumorigenesis, biological intervention of disease states such as Alzheimer's disease and other neurological disorders, diabetes, cancers and bone morphogenesis.
Preparing and procuring patents in pharmaceuticals and methods of use.
Providing support in due diligence, invalidity, inventorship and freedom to operate opinions.
| 